Arrevus

Arrevus is a clinical-stage biotechnology company dedicated to developing new therapies for orphan diseases. Their mission is to develop treatments that address unmet medical needs in areas with high treatment failure rates, limited therapeutic options, and severe conditions. Arrevus is advancing ARV-1801, a Phase III clinical program targeting acute exacerbations of cystic fibrosis lung disease. Arrevus is also advancing a preclinical program aimed at addressing unmet needs in oncology and antimicrobial resistance.